Loading...
•
Jun 30, 2021
Ligand Q2 2021 Earnings Report
Reported financial results with record revenues and progress across core technology platforms.
Key Takeaways
Ligand Pharmaceuticals reported a record $84.7 million in total revenues for Q2 2021, driven by strong Captisol sales and contract revenue, resulting in a net income of $30.7 million, or $1.79 per diluted share.
Total revenues for the second quarter of 2021 were a record $84.7 million, compared to $41.4 million for the same period in 2020.
Captisol sales were $62.5 million for the second quarter of 2021, compared to $24.5 million for the same period in 2020, driven by higher sales for use with remdesivir.
Net income for the second quarter of 2021 was $30.7 million, or $1.79 per diluted share, compared to net income of $22.1 million, or $1.32 per diluted share, for the same period in 2020.
Ligand is adjusting full-year 2021 guidance primarily to reflect lower expected Captisol revenue related to reduced demand for Captisol related to remdesivir.
Revenue by Segment
Forward Guidance
Ligand now expects full-year 2021 total revenues to be between $265 million and $275 million, and adjusted earnings per diluted share to be between $5.80 and $6.05.
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...